James M. Daly - 04 Jan 2022 Form 4 Insider Report for BELLICUM PHARMACEUTICALS, INC

Role
Director
Signature
/s/ Richard A. Fair, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Jan 2022
Net transactions value
$0
Form type
4
Filing time
06 Jan 2022, 08:39:13 UTC
Previous filing
06 Jul 2021
Next filing
06 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLCM Common Stock Options Exercise $0 +13,568 $0.000000 13,568 04 Jan 2022 Direct F1
transaction BLCM Common Stock Options Exercise $0 +809 +6% $0.000000 14,377 04 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLCM Restricted Stock Units Options Exercise $0 -13,568 -100% $0.000000* 0 04 Jan 2022 Common Stock 13,568 Direct F1, F2
transaction BLCM Restricted Stock Units Options Exercise $0 -809 -100% $0.000000* 0 04 Jan 2022 Common Stock 809 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock.
F2 The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021
F3 The RSUs granted on July 1, 2021 vest in full on January 4, 2022.